Drug profile · INN
tezepelumab
TEZSPIRE
tezepelumab (TEZSPIRE) is a thymic stromal lymphopoietin inhibitor.
EMA: approved Respiratory system (R03) R03DX11
Patents linked 0
Pipeline programs 9
News articles 0
Drug details — tezepelumab
- Class
- Respiratory system (R03)
- Route
- —
- Patents
- 0
- Programs
- 9
- Data quality
- 0.83
Quick answer
tezepelumab (TEZSPIRE) is a thymic stromal lymphopoietin inhibitor.
Key facts
INN tezepelumab
Brand TEZSPIRE
Mechanism Thymic stromal lymphopoietin inhibitor
Target Thymic stromal lymphopoietin
Therapeutic class Respiratory system (R03)
ATC code R03DX11
Mechanism of action
Thymic stromal lymphopoietin inhibitor
Primary target: Thymic stromal lymphopoietin
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is tezepelumab?
tezepelumab (TEZSPIRE) is a thymic stromal lymphopoietin inhibitor.
What is the brand name for tezepelumab?
TEZSPIRE is a marketed brand name for tezepelumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.